Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Rimegepant sulfate ODT by Pfizer for Irritable Bowel Syndrome: Likelihood of Approval
Rimegepant sulfate ODT is under clinical development by Pfizer and currently in Phase II for Irritable Bowel Syndrome. According to...
Palbociclib by Pfizer for Chordoma: Likelihood of Approval
Palbociclib is under clinical development by Pfizer and currently in Phase II for Chordoma. According to GlobalData, Phase II drugs...
Maplirpacept by Pfizer for Peripheral T-Cell Lymphomas (PTCL): Likelihood of Approval
Maplirpacept is under clinical development by Pfizer and currently in Phase I for Peripheral T-Cell Lymphomas (PTCL). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Fordadistrogene Movaparvovec?
Fordadistrogene Movaparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Duchenne Muscular Dystrophy. According...
PF-06425090 by Pfizer for Clostridioides difficile Infections (Clostridium difficile Associated Disease): Likelihood of Approval
PF-06425090 is under clinical development by Pfizer and currently in Phase III for Clostridioides difficile Infections (Clostridium difficile Associated Disease)....
PF-07799544 by Pfizer for Metastatic Melanoma: Likelihood of Approval
PF-07799544 is under clinical development by Pfizer and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase I...
Inclacumab by Pfizer for Sickle Cell Disease With Vaso-Occlusive Crisis: Likelihood of Approval
Inclacumab is under clinical development by Pfizer and currently in Phase III for Sickle Cell Disease With Vaso-Occlusive Crisis. According...
Sasanlimab by Pfizer for Solid Tumor: Likelihood of Approval
Sasanlimab is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PF-07799544 by Pfizer for Solid Tumor: Likelihood of Approval
PF-07799544 is under clinical development by Pfizer and currently in Phase I for Solid Tumor. According to GlobalData, Phase I...
PF-07264660 by Pfizer for Atopic Dermatitis (Atopic Eczema): Likelihood of Approval
PF-07264660 is under clinical development by Pfizer and currently in Phase II for Atopic Dermatitis (Atopic Eczema). According to GlobalData,...
PF-07261271 by Pfizer for Inflammatory Bowel Disease: Likelihood of Approval
PF-07261271 is under clinical development by Pfizer and currently in Phase I for Inflammatory Bowel Disease. According to GlobalData, Phase...
Bosutinib by Pfizer for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
Bosutinib is under clinical development by Pfizer and currently in Phase II for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic...
Binimetinib by Pfizer for Metastatic Colorectal Cancer: Likelihood of Approval
Binimetinib is under clinical development by Pfizer and currently in Phase II for Metastatic Colorectal Cancer. According to GlobalData, Phase...
Elranatamab by Pfizer for Multiple Myeloma (Kahler Disease): Likelihood of Approval
Elranatamab is under clinical development by Pfizer and currently in Phase III for Multiple Myeloma (Kahler Disease). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Pfizer's Marstacimab?
Marstacimab is a monoclonal antibody commercialized by Pfizer, with a leading Pre-Registration program in Hemophilia B (Factor IX Deficiency). According...
Risk adjusted net present value: What is the current valuation of Pfizer's Inclacumab?
Inclacumab is a monoclonal antibody commercialized by Pfizer, with a leading Phase III program in Sickle Cell Disease With Vaso-Occlusive...
Risk adjusted net present value: What is the current valuation of Pfizer's Sisunatovir Hydrochloride?
Sisunatovir Hydrochloride is a small molecule commercialized by Pfizer, with a leading Phase III program in Respiratory Syncytial Virus (RSV)...
Risk adjusted net present value: What is the current valuation of Pfizer's PF-06835375?
PF-06835375 is a biologic commercialized by Pfizer, with a leading Phase II program in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)....
Risk adjusted net present value: What is the current valuation of Pfizer's Maplirpacept?
Maplirpacept is a fusion protein commercialized by Pfizer, with a leading Phase II program in Primary Mediastinal B-Cell Lymphoma. According...
Risk adjusted net present value: What is the current valuation of Pfizer's Giroctocogene fitelparvovec?
Giroctocogene fitelparvovec is a gene therapy commercialized by Pfizer, with a leading Phase III program in Hemophilia A (Factor VIII...